Dana-Farber Cancer Institute - Merrimack Valley

Summary

Dana-Farber Cancer Institute - Merrimack Valley is a medical facility located in Methuen, Massachusetts. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Patient Adherence, Treatment Adherence and Compliance and other specialties. Dana-Farber Cancer Institute - Merrimack Valley is involved with conducting 3 clinical trials across 11 conditions. There are 3 research doctors associated with this hospital, such as Pedro M. Sanz-Altamira, Leticia Varella, MD, and Pedro Manuel Sanz-Altamira.

Top PIs

Clinical Trials running at Dana-Farber Cancer Institute - Merrimack Valley

Breast Cancer

Non-Small Cell Lung Cancer

Lung Cancer

CDK4/6 Inhibitors

for Metastatic Breast Cancer

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors. Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing). Note: Telehealth visits are allowed at any time per institutional guidelines. In addition, the study allows for remote consenting per institutional guidelines.

Recruiting

2 awards

Phase 3

3 criteria

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria